Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial.

IF 11.7 1区医学 Q1 CELL BIOLOGY

Cell Reports Medicine Pub Date : 2024-08-20 DOI:10.1016/j.xcrm.2024.101682

Anne-Laure Agrinier, Arianne Morissette, Laurence Daoust, Théo Gignac, Julie Marois, Thibault V Varin, Geneviève Pilon, Éric Larose, Claudia Gagnon, Yves Desjardins, Fernando F Anhê, Anne-Marie Carreau, Marie-Claude Vohl, André Marette

{"title":"Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial.","authors":"Anne-Laure Agrinier, Arianne Morissette, Laurence Daoust, Théo Gignac, Julie Marois, Thibault V Varin, Geneviève Pilon, Éric Larose, Claudia Gagnon, Yves Desjardins, Fernando F Anhê, Anne-Marie Carreau, Marie-Claude Vohl, André Marette","doi":"10.1016/j.xcrm.2024.101682","DOIUrl":null,"url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population with no effective drug treatments available. Previous animal studies reported that a polyphenol-rich extract from the Amazonian berry camu-camu (CC) prevented hepatic steatosis in a mouse model of diet-induced obesity. This study aims to determine the impact of CC on hepatic steatosis (primary outcome) and evaluate changes in metabolic and gut microbiota profiles (exploratory outcomes). A randomized, double-blind, placebo-controlled crossover trial is conducted on 30 adults with overweight and hypertriglyceridemia, who consume 1.5 g of CC capsules or placebo daily for 12 weeks. CC treatment decreases liver fat by 7.43%, while it increases by 8.42% during the placebo intervention, showing a significant difference of 15.85%. CC decreases plasma aspartate and alanine aminotransferases levels and promotes changes in gut microbiota composition. These findings support that polyphenol-rich prebiotic may reduce liver fat in adults with overweight, reducing the risk of developing NAFLD.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2024.101682","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population with no effective drug treatments available. Previous animal studies reported that a polyphenol-rich extract from the Amazonian berry camu-camu (CC) prevented hepatic steatosis in a mouse model of diet-induced obesity. This study aims to determine the impact of CC on hepatic steatosis (primary outcome) and evaluate changes in metabolic and gut microbiota profiles (exploratory outcomes). A randomized, double-blind, placebo-controlled crossover trial is conducted on 30 adults with overweight and hypertriglyceridemia, who consume 1.5 g of CC capsules or placebo daily for 12 weeks. CC treatment decreases liver fat by 7.43%, while it increases by 8.42% during the placebo intervention, showing a significant difference of 15.85%. CC decreases plasma aspartate and alanine aminotransferases levels and promotes changes in gut microbiota composition. These findings support that polyphenol-rich prebiotic may reduce liver fat in adults with overweight, reducing the risk of developing NAFLD.

Abstract Image

查看原文本刊更多论文

Camu-camu 可减少超重、高甘油三酯血症患者的肝脏脂肪变性和肝损伤指标：随机交叉试验

非酒精性脂肪肝（NAFLD）影响着 25% 的成年人，目前尚无有效的药物治疗方法。之前的动物研究报告称，从亚马逊浆果卡谬卡谬（CC）中提取的富含多酚的提取物可在饮食诱发肥胖的小鼠模型中预防肝脂肪变性。本研究旨在确定CC对肝脂肪变性的影响（主要结果），并评估代谢和肠道微生物群特征的变化（探索性结果）。这项随机、双盲、安慰剂对照交叉试验的对象是30名超重和高甘油三酯血症的成年人，他们每天服用1.5克CC胶囊或安慰剂，为期12周。CC治疗使肝脏脂肪减少7.43%，而安慰剂干预期间肝脏脂肪增加8.42%，显著差异为15.85%。CC能降低血浆天冬氨酸和丙氨酸转氨酶水平，并促进肠道微生物群组成的变化。这些研究结果表明，富含多酚的益生元可减少超重成年人的肝脏脂肪，降低患非酒精性脂肪肝的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

15.00

自引率

1.40%

发文量

231

审稿时长

40 days

期刊介绍： Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.

文献相关原料

公司名称	产品信息	采购帮参考价格